Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17115511 | 0.79 | — | — | |
| SCHEMBL14551907 | 0.78 | NOS3 (0.32) | NOS3NOS1NOS2 | |
| SCHEMBL12326723 | 0.78 | NOS3 (0.32) | NOS3NOS1NOS2 | |
| SCHEMBL29281259 | 0.74 | NOS3 (0.39) | NOS3NOS1NOS2 | |
| SCHEMBL11580763 | 0.72 | MAPT (0.34) | MAPTGAATP53RECQLPOLB | |
| SCHEMBL24097335 | 0.70 | NOS3 (0.36) | MAPTNOS3NOS1NOS2 | |
| SCHEMBL1397564 | 0.70 | NOS3 (0.36) | MAPTNOS3NOS1NOS2 | |
| SCHEMBL21496729 | 0.70 | NOS3 (0.36) | MAPTNOS3NOS1NOS2 | |
| SCHEMBL7832377 | 0.70 | TSHR (0.36) | NOS3NOS1NOS2 | |
| SCHEMBL27303254 | 0.70 | CRBN (0.46) | NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570666-B2 | Furoindazole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-10 | — | — | US | disclosed |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250296910-A1 | BENZAMIDE ENAMINONE DERIVATIVES AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND EASTERN SHORE | 2025-09-25 | — | — | US | disclosed |
| EP-4077334-B1 | FUROINDAZOLE DERIVATIVES | BAYER AG (DE) | 2025-03-12 | — | — | EP | disclosed |
| CN-119451940-A | Benzamide enaminone derivatives and methods of use thereof | 马里兰大学东岸分校 | 2025-02-14 | — | — | CN | disclosed |
| EP-4499603-A1 | BENZAMIDE ENAMINONE DERIVATIVES AND METHODS OF USE THEREOF | University of Maryland, Eastern Shore (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240382438-A1 | Calcium Channel Blockers and Methods Thereof | UNIV OF MARYLAND EASTERN SHORE (US) | 2024-11-21 | — | — | US | disclosed |
| CN-115135656-B | Furanoindazole derivatives | 拜耳公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-3632903-B1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023192814-A1 | BENZAMIDE ENAMINONE DERIVATIVES AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, EASTERN SHORE (US) | 2023-10-05 | — | — | WO | disclosed |
| US-8329732-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-12-11 | — | — | US | disclosed |
| US-8329732-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-12-11 | — | — | US | disclosed |
| US-8329732-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-12-11 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2344474-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010026124-A1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MAPT 3029/4885GAA 1084/4885NOS3 4258/4885 |
| US-20240382438-A1 | Calcium Channel Blockers and Methods Thereof | CACNB2, CACNA1B, CACNB1 | MAPT 445/4885GAA 934/4885NOS3 1730/4885 |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | MAPT 3029/4885GAA 1084/4885NOS3 4258/4885 |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | CNR1, SCN1B, OPRL1 | MAPT 4460/4885GAA 3337/4885NOS3 1882/4885 |
| US-12570666-B2 | Furoindazole derivatives | FURIN, CYP2F1, CYP3A7 | MAPT 4672/4885GAA 599/4885NOS3 3978/4885 |
| US-20250296910-A1 | BENZAMIDE ENAMINONE DERIVATIVES AND METHODS OF USE THEREOF | GABBR2, GABBR1, GABRA5 | MAPT 2166/4885GAA 190/4885NOS3 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.